Adamas Pharmaceuticals is developing novel therapeutics for the treatment of central nervous system (CNS)
disorders by optimizing the pharmacokinetic profiles of approved drugs, alone and as components of fixed-dose
combination products. The Company is currently advancing a pipeline of aminoadamantane-based drug candidates
for the treatment of Parkinson’s disease, Alzheimer’s disease and other CNS disorders, with multiple product
candidates in late-stage clinical development including:
- ADS-5102 (amantadine HCl ER) for CNS disorders, initially being investigated
for levodopa-induced dyskinesia (LID) in Parkinson's disease;
- MDX-8704 (memantine HCl ER/donepezil HCl), being investigated for the treatment
of moderate to severe dementia of the Alzheimer's type, being developed in collaboration with Forest
Laboratories, Inc. (US market);
- ADS-8704 (memantine HCl ER/donepezil HCl), being investigated for the treatment
of moderate to severe dementia of the Alzheimer's type (ex-US market).
Adamas' experienced team has developed an integrated process that combines in-depth knowledge of CNS markets
and unmet medical needs, the interactions between drug plasma concentrations and clinical effects, regulatory
strategy and pharmaceutical development to identify, optimize, protect and then develop proprietary
controlled-release and fixed-dose combination products. The Company's current product candidates are based on
an understanding of the relationship between blood level changes and side effects that may result in extended-release
products with higher dose strengths than immediate-release formulations of aminoadamantanes.
Adamas has established a substantial intellectual property portfolio encompassing pharmacokinetics, compositions
and methods of use for extended-release amantadine and memantine products. Adamas plans to advance its product
candidates through approval and commercialize products in the United States through a specialty CNS sales force.
In addition to our CNS programs, Adamas is developing ADS-8902, (amantadine HCl/ oseltamivir/ribavirin) for
the treatment of severe influenza infection in collaboration with the National Institutes of Health and US
Navy. ADS-8902 exploits amantadine's second mode of action as an antiviral, which, when combined with
oseltamivir and ribavirin, blocks influenza replication at multiple points in the virus life cycle.
Back to top »